MOUNTAINSIDE, NJ--(Marketwire - 05/23/11) - PROTEONOMIX, INC. (OTC.BB:PROT - News), a biotechnology company ("Proteonomix" or the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to announce the results of animal studies involving the Company's UMK-121 technology.The pre-clinical studies were conducted in rodents and a large animal model to confirm the potential of the UMK-121 technology to mobilize Stromal Stem Cells ("SSCs") into the peripheral blood of animals, thereby making the SSCs available for therapeutic uses. |
